Among Persons With HIV, More Finish Short-Course TB Prophylaxis
Treatment completion 90.4 percent for three months of rifapentine-isoniazid versus 50.5 percent for six months of isoniazid
Tuberculosis
Four-Month Rifapentine Regimen With Moxifloxacin Noninferior for TB
Rifapentine-based regimen with moxifloxacin noninferior to six-month control regimen of rifampin, isoniazid, pyrazinamide, ethambutol
MPR Weekly Dose Podcast Episode 55
Results from the survey assessing willingness to receive a COVID vaccine; Dr. Fauci shares that he is ‘cautiously optimistic’ a vaccine could arrive before year’s end; And the breaking news that remdesivir (Veklury) has gained FDA approval.
Shorter-Course Regimen Safe, Effective for TB Treatment
The randomized, open-label, controlled trial (Study 31/A5349) had more than 2500 participants ages 12 years and older and included 214 people with HIV.
FDA: Tuberculosis Drugs May Contain Nitrosamine Impurities
Currently, there is no available evidence to assess the carcinogenic potential of MNP and CPNP.
Short-Course Rifamycin-Based Regimens Preferred for Latent TB
Shorter regimens favored over longer course of isoniazid monotherapy for latent TB infection.
Review: Areas of Pediatric Medical Overuse Identified
A recent systematic review identified several established as well as emerging practices utilized in the pediatric setting that were associated with overuse of medical care.
Pretomanid Approved as Part of a New Regimen for Highly Drug-Resistant Tuberculosis
The FDA has approved pretomanid tablets (TB Alliance) in combination with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).
FDA Panel Votes on Treatment for Extensively Drug Resistant, Multidrug Resistant TB
The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of pretomanid, as part of a combination regimen with bedaquiline and linezolid, for the treatment of pulmonary extensively drug resistant, treatment intolerant, or nonresponsive multidrug resistant tuberculosis.
Aplisol Shortage Prompts CDC to Issue New Recommendations for TB Testing
The CDC announced an expected 3 to 10 month shortage of Aplisol (tuberculin purified protein derivative [PPD], diluted), used as an aid in the diagnosis of tuberculosis.
